Key Highlights
- PolyPid shares are trading down 3.11% at $6.40 versus a prior close of $6.60.
- The FDA goal date for D-PLEX100 is November 28, 2026.
- Azurity is preparing a U.S. launch in early 2027, subject to approval.
- Azurity has paid $30 million so far, with over $290 million in further milestones.
- Cash should fund operations into 2028.
PolyPid (NASDAQ:PYPD) is trading down 3.11% at $6.40 as the November 28 FDA goal date for D-PLEX100 approaches. The Israeli company reported a narrower third quarter loss and highlighted launch preparation.
FDA Review
D-PLEX100, for prevention of surgical site infection in colorectal surgery, is under priority review with a goal date of November 28, 2026. Labeling discussions are underway. Azurity is preparing a U.S. launch in early 2027, subject to approval, with adoption expected to build account by account over several months through hospital committee reviews.
Reimbursement
A new technology add-on payment application has been submitted to CMS, with a decision expected in August 2027 and an October effective date. If granted, it would reimburse hospitals up to 75% of product cost above the standard payment. Market research showed about 90% of pharmacists willing to add the product to formulary, rising to 100% with the add-on payment.
Azurity Deal
Azurity has paid $30 million so far, including a $15 million milestone received in early October when the application was accepted, with over $290 million in additional development, regulatory and sales milestones. Label expansion to broader abdominal surgery, about 4 million U.S. surgeries a year, will begin FDA communications in the fourth quarter, and Azurity will fund the clinical work.
Europe
The European Medicines Agency validated the Marketing application submitted September 14, with a decision expected in the second half of 2027 and a potential launch in 2028. European rights reverted to PolyPid after the Advance Pharma agreement was terminated, and the company is in partner discussions.
Funding and Analysts
Management believes cash plus Azurity proceeds will fund operations into 2028. H.C. Wainwright reiterated Buy with a $13 target, and two analysts rate the stock a Strong Buy. The stock trades in a 52-week range of $3.50 to $7.15.
The FDA Decision Decides the Next Move
Shares trade near the top of their range into a binary regulatory event. Investors will watch the November 28 decision and final labeling, which affects the Azurity launch and further milestone payments.
Launch timing in early 2027 and the CMS add-on payment decision are the next markers.






Please wait processing your request...